Protara Therapeutics (NASDAQ: TARA) CCO has 6,008 RSU shares withheld for taxes

Rhea-AI Filing Summary

Protara Therapeutics, Inc. Chief Commercial Officer William Conkling reported a routine tax-related share disposition. On June 2, 2026, 6,008 shares of common stock were withheld by the company at $4.34 per share to cover income tax obligations from the vesting of Restricted Stock Unit Awards granted on June 2, 2025. After this withholding, Conkling directly holds 69,992 shares of Protara common stock. This transaction was not an open-market purchase or sale, but an administrative step tied to equity compensation.

Insights

Equity compensation analyst

Routine tax withholding on RSU vesting; no open-market trade.

The filing shows Protara Therapeutics Chief Commercial Officer William Conkling had 6,008 shares withheld at $4.34 per share to satisfy income taxes on vesting Restricted Stock Units granted on June 2, 2025. Code F indicates this was a tax-withholding disposition.

This type of transaction is a standard equity-compensation mechanism rather than a discretionary trade in the company’s stock. Following the withholding, Conkling directly holds 69,992 common shares, suggesting he maintains a meaningful equity stake. There are no remaining derivative positions listed in this filing.

Because the event is administrative and not an open-market buy or sell, it typically carries limited informational value about management’s view of the stock. Future company filings may provide additional context on overall executive equity holdings and compensation structure.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider CONKLING WILLIAM

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	6,008	$4.34	$26K

Holdings After Transaction: Common Stock — 69,992 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares withheld for taxes: 6,008 shares Withholding price: $4.34 per share Shares held after transaction: 69,992 shares +2 more

5 metrics

Shares withheld for taxes 6,008 shares Withholding to satisfy income tax obligations on RSU vesting

Withholding price $4.34 per share Value applied to withheld common stock

Shares held after transaction 69,992 shares Directly owned common stock following withholding

Transaction date June 2, 2026 Date of tax-withholding disposition

RSU grant date June 2, 2025 Grant date of Restricted Stock Unit Awards that vested

Key Terms

Restricted Stock Unit Awards, income tax obligations, transaction code F, Form 4

4 terms

Restricted Stock Unit Awards financial

"associated with the vesting of Restricted Stock Unit Awards granted to the Reporting Person on June 2, 2025"

Restricted stock unit awards are company promises to deliver a specific number of shares to employees or service providers in the future once conditions—such as staying with the company for a set time or meeting performance targets—are met. They matter to investors because when the promises convert into actual shares they increase the total share count and can reduce earnings per share, while also aligning recipients’ interests with stock performance much like deferred pay that turns into ownership if goals are met.

income tax obligations financial

"Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting"

transaction code F regulatory

"transaction_code_description": "Payment of exercise price or tax liability by delivering securities"

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CONKLING WILLIAM

(Last) (First) (Middle)

C/O PROTARA THERAPEUTICS, INC.

345 PARK AVENUE SOUTH 3RD FLOOR

(Street)

NEW YORK NEW YORK 10010

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Protara Therapeutics, Inc. [ TARA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/02/2026		F		6,008(1)	D	$4.34	69,992	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. 1. Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of Restricted Stock Unit Awards granted to the Reporting Person on June 2, 2025.

Remarks:

	William Conkling	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Protara Therapeutics (TARA) report for William Conkling?

Protara Therapeutics reported that Chief Commercial Officer William Conkling had 6,008 common shares withheld to cover taxes on vesting RSUs. The shares were valued at $4.34 each, reflecting a routine equity-compensation tax withholding, not an open-market stock sale.

Was the Protara Therapeutics (TARA) Form 4 transaction an open-market sale?

The Form 4 transaction was not an open-market sale. It reflects 6,008 shares withheld by the issuer to satisfy income tax obligations from vesting Restricted Stock Unit Awards, a standard administrative process in stock-based compensation plans.

How many Protara Therapeutics (TARA) shares does William Conkling hold after this Form 4?

After the tax-withholding transaction, William Conkling directly holds 69,992 shares of Protara Therapeutics common stock. This post-transaction figure comes directly from the Form 4 and shows his remaining equity position following the RSU vesting-related share withholding.

What does transaction code F mean in the Protara Therapeutics (TARA) Form 4?

Transaction code F on the Form 4 indicates shares were disposed of to pay an exercise price or tax liability. Here, it represents 6,008 shares withheld by Protara to cover income taxes due on the vesting of Restricted Stock Unit Awards granted to William Conkling.

What triggered the share withholding for Protara Therapeutics (TARA) executive William Conkling?

The withholding was triggered by the vesting of Restricted Stock Unit Awards granted to William Conkling on June 2, 2025. When these RSUs vested, 6,008 shares were retained by the issuer at $4.34 per share to satisfy associated income tax obligations.

Does the Protara Therapeutics (TARA) Form 4 show any option exercises or derivative transactions?

The Form 4 does not show any option exercises or other derivative transactions. It reports only a single non-derivative transaction where 6,008 common shares were withheld for tax obligations linked to vesting Restricted Stock Unit Awards, with no remaining derivatives listed.